6 completed, 2 recruiting, 2 withdrawn, 1 active not recruiting. 12 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 6, Recruiting 2, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1 |
Follow imetelstat: new trials by email Literature Review of imetelstat trials Research Report on imetelstat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT imetelstat - High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation | Phase 1 | Not yet recruiting | University of Wisconsin, Madison | 27 | 2027-02-01 | 2026-11-02 |
| Imetelstat Combinations in Relapsed AML Imetelstat, Azacitidine, Venetoclax - Relapsed Acute Myeloid Leukemia | Phase 1 | Recruiting | Douglas Tremblay | 36 | 2026-01-02 | 2026-04-22 |
| A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome | Phase 1 | Recruiting | Children's Oncology Group | 36 | 2025-02-04 | 2026-08-25 |
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis Imetelstat sodium, Ruxolitinib - Myelofibrosis | Phase 1 | Active not recruiting | Geron Corporation | 30 | 2022-05-04 | 2026-08-26 |
| Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma Imetelstat - Neuroblastoma | Phase 1 | Withdrawn | NCIC Clinical Trials Group | 2013-07-30 | 2020-09-21 | |
| Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma Imetelstat - Solid Tumors, Lymphoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2012-03-01 | 2012-11-21 | |
| Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma imetelstat sodium, laboratory biomarker analysis, pharmacological study - Brain and Central Nervous System Tumors, Lymphoma | Phase 1 | Completed | Children's Oncology Group | 34 | 2011-05-01 | 2014-01-30 |
| A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer GRN163L in combination with trastuzumab - Breast Neoplasms | Phase 1 | Completed | Indiana University | 10 | 2011-01-01 | 2015-10-27 |
| Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma Imetelstat Sodium (GRN163L) - Multiple Myeloma | Phase 1 | Completed | Geron Corporation | 40 | 2008-07-01 | 2015-12-24 |
| Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma Imetelstat Sodium (GRN163L) - Multiple Myeloma | Phase 1 | Completed | Geron Corporation | 20 | 2007-11-01 | 2015-12-24 |
| Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer Imetelstat Sodium (GRN163L) - Lung Cancer | Phase 1 | Completed | Geron Corporation | 27 | 2007-07-01 | 2015-12-24 |
| Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies Imetelstat Sodium (GRN163L) - Solid Tumor Malignancies | Phase 1 | Completed | Geron Corporation | 85 | 2006-03-01 | 2015-12-24 |
Recurrence (4) · Leukemia, Myeloid, Acute (2) · Lymphoma (2) · Multiple Myeloma (2) · Neoplasms, Plasma Cell (2) · Primary Myelofibrosis (2) · Astrocytoma (1) · Breast Neoplasms (1) · Burkitt Lymphoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Central Nervous System Neoplasms (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Glioblastoma (1) · Hodgkin Disease (1) · Immunoblastic Lymphadenopathy (1)
Geron Corporation (5) · Children's Oncology Group (2) · Douglas Tremblay (1) · Indiana University (1) · NCIC Clinical Trials Group (1) · National Cancer Institute (NCI) (1) · University of Wisconsin, Madison (1)
United States (10) · Canada (2)
Alexandra M Stevens (1) · Douglas Tremblay, MD (1) · Hongtao Liu, MD, PhD (1) · John Mascarenhas, MD (1) · Kathy Miller, MD (1) · Michelle Mudge-Riley, DO (1) · Patrick A. Thompson, MD (1) · Stephen Kelsey, MD (1) · Steve Kelsey, MD (1) · Victor Lewis (1) · William L Dahut, M.D. (1)
UM1CA228823 (1)